NY-THE-BODY-SHOP
11.5.2022 17:02:10 CEST | Business Wire | Press release
Millions of young people are missing from public life. With the climate crisis, global conflict and generational inequalities running rampant, the inputs, perspectives and representation of youth are needed more than ever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005499/en/
Almost half the world's population is under 30. Yet, they make up only 2.6% of parliamentarians around the world**. The average age of a world leader is currently 62***. Of all the parliaments in the world, 37% do not have a single Member of Parliament (MP) under age 30** and less than 1% of these young MPs are women.
Young people have the right to be included in political decisions that affect them, however, numerous barriers prevent their participation. The Body Shop and the Office of the United Nations Secretary-General's Envoy on Youth are collaborating to change this through the global Be Seen Be Heard campaign, which seeks to create long-term structural changes to decision-making to be more inclusive of young people.
It is launched today with the release of a research piece titled ‘ Be Seen Be Heard: Understanding young people’s political participation’.
The research includes the largest-ever survey carried out by The Body Shop, covering 26 countries with 27,043 respondents. It found that 82% of people surveyed agree that political systems need drastic reform to be fit for the future.
Two in three people also agree that the age balance in politics is wrong, with 8 in 10 people of all ages believing the ideal voting age (the age when someone can first vote) is 16 to 18, despite that in most countries the voting age is 18 or over. A third of those under age 30 surveyed would consider running for office versus only a fifth of those over age 30. People across all age groups agree that more opportunities for younger people to have a say in policy development and/or change would make political systems better.
David Boynton, CEO of The Body Shop says, “Our position is clear. The world’s problems cannot be solved by the same people making the same choices. The majority of young people are positive about the future, and we need to hear their views and ideas inside the halls of power. We will use our global reach to galvanise awareness and support, as we have in the past.”
Jayathma Wickramanayake, the United Nations Secretary-General’s Envoy on Youth says, “The intergenerational gap in power, influence and trust constitutes one of the biggest challenges of our time. Participation is a right, and a lack of youth representation where decisions are made contributes to a growing mistrust towards political institutions and a sense of alienation from elected leaders, caused by policies that do not reflect the priorities of youth, mirror their concerns or speak their language. This campaign is an opportunity to change that.”
The report suggests that young people’s participation in public decision-making could be improved long-term by a number of initiatives including; lowering voting ages, increasing formal youth representation, removing barriers for young people to participate in public decision-making, simplifying registration for first-time voters and improving young people’s leadership skills.
The campaign is launching globally in May 2022 and will run until mid-2025, driven by action in over 2,600 Body Shop stores in 75 countries, across six continents.
More information here.
Ends
** https://www.ipu.org/our-impact/youth-empowerment/data-youth-participation
*** REIGN Dataset | REIGN (oefdatascience.github.io)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005499/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
